Who
Vicki L. Sato
Director
Company insider
Files Form 4 as: Director, Allogene Therapeutics; Director, Vir Biotechnology; Director, Denali Therapeutics; Director, Akouos; Director, Bristol-Myers Squibb; Director, BorgWarner; Director, Syros Pharmaceuticals; Director, Revvity.
In numbers
- Trades disclosed
- 262
- Buys
- 0
- Sells
- 73
- Bought
- $0
- Sold
- $20.9M
- Companies
- 10
- Companies where not an officer
- 10
- First trade
- 2 May 2006
- Last trade
- 18 Jun 2026
- Last filed
- 23 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Jun 2026filed 23 Jun 2026 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —95,400 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —95,400 at $0.00 | filing |
| 1 May 2026filed 4 May 2026 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Sold | $221K22,000 at $10.05 | filing |
| 1 May 2026filed 4 May 2026 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Sold | $221K22,000 at $10.05 | filing |
| 1 Apr 2026filed 2 Apr 2026 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Sold | $200K22,000 at $9.07 | filing |
| 1 Apr 2026filed 2 Apr 2026 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Sold | $200K22,000 at $9.07 | filing |
| 2 Mar 2026filed 3 Mar 2026 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Sold | $207K21,800 at $9.50 | filing |
| 2 Mar 2026filed 3 Mar 2026 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Sold | $1,996200 at $9.98 | filing |
| 2 Mar 2026filed 3 Mar 2026 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Sold | $207K21,800 at $9.50 | filing |
| 2 Mar 2026filed 3 Mar 2026 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Sold | $1,996200 at $9.98 | filing |
| 24 Feb 2026filed 26 Feb 2026 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Code M | $63K42,377 at $1.49 | filing |
| 24 Feb 2026filed 26 Feb 2026 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Sold | $411K42,177 at $9.75 | filing |
| 24 Feb 2026filed 26 Feb 2026 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Sold | $2,052200 at $10.26 | filing |
| 24 Feb 2026filed 26 Feb 2026 | VIR Vir Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code M | —42,377 at $0.00 | filing |
| 24 Feb 2026filed 26 Feb 2026 | VIR Vir Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code M | —42,377 at $0.00 | filing |
| 24 Feb 2026filed 26 Feb 2026 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Code M | $63K42,377 at $1.49 | filing |
| 24 Feb 2026filed 26 Feb 2026 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Sold | $411K42,177 at $9.75 | filing |
| 24 Feb 2026filed 26 Feb 2026 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Sold | $2,052200 at $10.26 | filing |
| 2 Feb 2026filed 3 Feb 2026 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Sold | $170K22,000 at $7.71 | filing |
| 2 Feb 2026filed 3 Feb 2026 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Sold | $170K22,000 at $7.71 | filing |
News
Vir Biotechnology (NASDAQ:VIR) Reaches New 12-Month High – Here's What HappenedVIR · tickerreport.com · 12 Oct 2026Vir Biotechnology (NASDAQ:VIR) vs. uniQure (NASDAQ:QURE) Critical ContrastVIR · dailypolitical.com · 11 Oct 2026Vir Biotechnology (NASDAQ:VIR) Price Target Raised to $22.00VIR · tickerreport.com · 10 Oct 2026
0 headlines in the last 90 days name Vicki L. Sato; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.